AFT Pharmaceuticals today announced record revenue for the year to the end of Mar 2023 and a maiden dividend.
Annual operating revenue reached $156.6 million, up 20% from the $130.3 million in the same period a year ago.
AFT has an operating profit of $19.7 million in line with the prior year's $20.4 million which was bolstered by significant licensing income.
Operating profit from product sales and royalties (excluding licensing income) rose 38% to $18.8 million from $13.7 million in the prior year, despite increased investment in growth opportunities.
EBITDA is steady at $21.4 million with net profit after tax of $10.7 million amid higher finance costs and a return to paying tax.
Net debt at $29.9 million in line with $29.3 million at the end of Mar 2022.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 May 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 May 23
